Dexmedetomidine Alleviates Sleep Rhythm Abnormalities in Chronic Sleep‐Deprived Mice via Modulation of SIK3 / HDAC4 /5 Signalling
Clinical and Experimental Pharmacology and Physiology · 2026
DOI: 10.1111/1440-1681.70086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, 2026. Verfasst von Zhengye Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Dexmedetomidine, Sleep Deprivation, Signal Transduction, Histone Deacetylases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Research project of Changzhou Medical Center, Changzhou Municipal Health Commission Science and Technology Program Fund, Research, development and verification of personalized multi-mode innovative diagnosis and treatment intervention scheme of integrated traditional Chinese and….
Abstract (Originalsprache)
Background
Sleep deprivation (SD) often disrupts normal sleep patterns, leading to anxiety‐like behaviours and cognitive impairments. Dexmedetomidine (DEX), a highly selective α‐2 adrenergic agonist, has been reported to improve postoperative sleep quality and alleviate cognitive deficits. Evidence indicates that DEX can regulate the expression of histone deacetylase 5 (HDAC5), a substrate of the sleep‐regulating molecule salt‐inducible kinase 3 (SIK3). However, its specific role and the underlying mechanisms in regulating sleep structure remain unclear. This study aims to examine DEX's effects and potential mechanisms in regulating sleep structure in sleep‐deprived mice.
Methods
C57BL/6J mice were subjected to chronic sleep deprivation (CSD) for 20 h (from 5 to 1 PM the next day), followed by administration of DEX at 1 and 3 PM daily for 7 consecutive days. Emotional behaviours were evaluated using the open‐field test. Sleep patterns were assessed during the recovery period using EEG/EMG. Golgi‐Cox staining was used to determine neuronal dendritic damage. Western blotting was employed to detect the SIK3/HDAC4/5 pathway‐related protein levels.
Results
CSD disrupted the sleep structure of mice during the recovery period and induced anxiety‐like behaviour and neuronal dendritic damage. DEX administration alleviated the above effects caused by CSD. Mechanistically, DEX activated SIK3/HDAC4/5 signalling in CSD mice, while inhibition of SIK3 with a specific inhibitor attenuated DEX's effects on the pathway activation.
Conclusion
DEX can alleviate sleep rhythm disturbances caused by CSD in mice possibly via modulation of the SIK3/HDAC4/5 pathway, thereby improving anxiety‐like behaviours and cognitive function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, Jiangsu, China.
Förderung
- Research project of Changzhou Medical Center
- Changzhou Municipal Health Commission Science and Technology Program Fund
- Research, development and verification of personalized multi-mode innovative diagnosis and treatment intervention scheme of integrated traditional Chinese and…
Zitieren
APA
Wang, Z., Ding, Y., Zhou, Y., & Wu, Z. (2026). Dexmedetomidine Alleviates Sleep Rhythm Abnormalities in Chronic Sleep‐Deprived Mice via Modulation of SIK3 / HDAC4 /5 Signalling. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/1440-1681.70086
Vancouver
Wang Z, Ding Y, Zhou Y, Wu Z. Dexmedetomidine Alleviates Sleep Rhythm Abnormalities in Chronic Sleep‐Deprived Mice via Modulation of SIK3 / HDAC4 /5 Signalling. Clinical and Experimental Pharmacology and Physiology. 2026. doi:10.1111/1440-1681.70086
BibTeX
@article{Wang2026,
author = {Wang, Zhengye and Ding, Yitong and Zhou, Yonghong and Wu, Zhouquan},
title = {Dexmedetomidine Alleviates Sleep Rhythm Abnormalities in Chronic Sleep‐Deprived Mice via Modulation of SIK3 / HDAC4 /5 Signalling},
journal = {Clinical and Experimental Pharmacology and Physiology},
year = {2026},
doi = {10.1111/1440-1681.70086}
}
EUVIMED